xNNPCD identifies regulators of programmed cell death by integrating perturbation transcriptomes with cancer dependency profiles

Avatar
Poster
Voice is AI-generated
Connected to paperThis paper is a preprint and has not been certified by peer review

xNNPCD identifies regulators of programmed cell death by integrating perturbation transcriptomes with cancer dependency profiles

Authors

Yin, Q.; Chen, L.

Abstract

Programmed cell death (PCD) encompasses multiple regulated processes whose dysregulation shapes cancer fitness, yet current computational studies largely use known PCD genes for prognosis rather than discovering regulators. We developed xNNPCD, an interpretable neural-network framework that links CRISPR-Cas9 perturbation signatures from CMap to gene dependency profiles from DepMap. The model constrains hidden neurons to five PCD pathways and iteratively refines a prior gene-pathway mask matrix derived from GO, KEGG, and Reactome using pathway-neuron ablation. This converts binary gene-pathway relationships into continuous-valued associations and improves dependency prediction over random forests, standard fully connected multi-layer perceptron, and its own non-iterative variant. The learned matrix recovers annotated death regulators and nominates candidate regulators, including RPL23A, HSPA5, SNRPA1, SLC6A2, and ASAH1; combined with dependency scores, it further separates pathway coupling from regulatory direction. Transferring the refined relationship matrix and learned weights to compound-induced perturbation data enables in silico drug screening, identifying BRD-K19103580 and decitabine as targeted therapeutic agents for apoptosis and ferroptosis, respectively. The pathway-resolved drug profiles can facilitate the rational design of combination therapies targeting complementary PCD pathways to overcome single-pathway resistance. Overall, xNNPCD offers a generalizable, interpretable approach for mapping the regulatory landscape and elucidating the molecular processes of PCD in cancer.

Follow Us on

0 comments

Add comment